Background: Negative symptoms in schizophrenia are heterogeneous and
multidimensional; effective treatments are lacking. Cariprazine, a dopamine D3-preferring …

Background Although predominant negative symptoms of schizophrenia can be severe
enough to cause persistent impairment, effective treatment options are lacking. We aimed to …

Schizophrenia affects various symptom domains, including positive and negative symptoms,
mood, and cognition. Cariprazine, a dopamine D 3/D 2 receptor partial agonist and …

Although currently approved antipsychotics exert efficacy on positive symptoms of
schizophrenia, treatments for negative symptoms remain a major unmet need. Post hoc …

Abstract This 6-week, double-blind, placebo-controlled, proof-of-concept study evaluated the
efficacy, safety, and tolerability of low-dose (1.5–4.5 mg/day) and high-dose (6–12 mg/day) …

Understanding how rating scale improvement corresponds to a clinical impression in
patients with negative symptoms of schizophrenia may help define the clinical relevance of …

Negative symptoms and cognitive impairment associated with schizophrenia are strongly
associated with poor functional outcome and reduced quality of life and remain an unmet …

Objective: Although most patients with schizophrenia are not aggressive, individuals with the
disorder have increased risk of hostile behavior. Cariprazine, a dopamine D 3 and D 2 …

The clinical presentation of schizophrenia encompasses symptoms divided into three
dimensions: positive, negative, and cognitive. Negative symptoms (NS), in particular, have a …

The aim of the study was to examine the effectiveness and safety of cariprazine in routine
psychiatric settings on schizophrenia patients with negative symptoms who have been …